Markets:

Overview

News

Currencies

International

Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

6.385 -0.075 (-1.16%)

Streaming Delayed Price Updated: 10:47 AM EDT, Aug 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run ↗

July 12, 2026

Nagendran Sukumar executed the sale under a pre-established Rule 10b5-1 trading plan, retaining 936,410 shares worth $5.94 million.

Via The Motley Fool

Topics Regulatory Compliance

Taysha (TSHA) Q1 2026 Earnings Transcript ↗

May 07, 2026

Taysha (TSHA) Q1 2026 Earnings Transcript

Via The Motley Fool

Taysha Gene Therapies (NASDAQ:TSHA) Reports Q1 2026 Miss, Reaffirms FDA Alignment on TSHA-102 Approval Path ↗

May 06, 2026

Via Chartmill

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug...

Via MarketMinute

Topics Intellectual Property Lawsuit

Taysha Gene Therapies Inc (NASDAQ:TSHA) Reports Q4 2025 Revenue Beat and Key Rett Syndrome Program Updates ↗

March 19, 2026

Via Chartmill

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.

Via The Motley Fool

Taysha (TSHA) Q4 2025 Earnings Call Transcript ↗

March 19, 2026

Taysha (TSHA) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Taysha Gene Therapies Inc (NASDAQ:TSHA) Stock Slumps on Q3 Revenue Miss Despite Key Regulatory Win for TSHA-102 ↗

November 04, 2025

Taysha Gene Therapies stock fell after Q3 results, with a revenue miss overshadowing positive FDA Breakthrough Therapy designation for its Rett syndrome drug.

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

What's Next: Taysha Gene Therapies's Earnings Preview ↗

August 11, 2025

Via Benzinga

Where Taysha Gene Therapies Stands With Analysts ↗

June 02, 2025

Via Benzinga

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Why Is Taysha Gene Therapies Stock Falling Friday? ↗

October 17, 2025

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.

Via Benzinga

Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals ↗

October 03, 2025

Taysha shares jumped after analysts at Baird, H.C. Wainwright, and Needham turned bullish, citing FDA alignment and an expedited approval path for its Rett syndrome therapy.

Via Stocktwits

Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience

October 02, 2025

On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Demystifying Taysha Gene Therapies: Insights From 6 Analyst Reviews ↗

October 02, 2025

Via Benzinga

Discover the most active stocks in Thursday's session. ↗

October 02, 2025

These stocks are making the most noise in today's session. Stay tuned for the latest updates!

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 02, 2025

Via Benzinga

Here are the top movers in Thursday's session. ↗

October 02, 2025

Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday ↗

October 02, 2025

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

Via Benzinga

Topics Stocks

Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy ↗

October 02, 2025

Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102.

Via Stocktwits

Which stocks are gapping on Thursday? ↗

October 02, 2025

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Top 2 Health Care Stocks That May Keep You Up At Night This Month ↗

October 02, 2025

Via Benzinga

What's Driving the Market Sentiment Around Taysha Gene Therapies? ↗

September 18, 2025

Via Benzinga

Is Taysha Gene Therapies Gaining or Losing Market Support? ↗

August 25, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through 11 Analysts ↗

August 13, 2025

Via Benzinga

Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock ↗

July 01, 2025

Via Benzinga

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data ↗

June 03, 2025

Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program.

Via Stocktwits

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday? ↗

May 29, 2025

Taysha shared the TSHA-102 trial plan after FDA alignment and reported 100% milestone gains with no serious adverse events in Rett syndrome patients.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.